Orthobiologics was Xtant Medical Holdings’s largest product and service line in fiscal 2025, bringing in $72.89M of $152.65M (48%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Orthobiologics | $47.14M | $58.61M | $66.42M | $72.89M | ||||
| Spinal Implant | $10.83M | $32.70M | $49.35M | $42.31M | ||||
| License Revenue | — | — | $1.50M | $18.72M | ||||
| License | — | — | $1.50M | $18.72M | ||||
| Other Revenue | — | — | — | — | ||||
| Total | $57.97M | $91.30M | $118.77M | $152.65M |
Xtant Medical Holdings brought in $152.65M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 28.5% from $118.77M in fiscal 2024. Orthobiologics was the largest at $72.89M (47.8%), ahead of Spinal Implant at $42.31M (27.7%) and License Revenue at $18.72M (12.3%). The remaining line, License, brought in $18.72M.
Compared with fiscal 2024, License Revenue grew fastest, up 1,146.5% to $18.72M, while Spinal Implant fell the most, down 14.3% to $42.31M.
Xtant Medical Holdings began breaking out License Revenue in fiscal 2024 and License in fiscal 2024.
United States was Xtant Medical Holdings’s largest region in fiscal 2025, bringing in $122.45M of $133.93M (91%).
| Geography | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $57.16M | $85.86M | $105.52M | $122.45M | ||||||||
| Us | — | — | — | — | ||||||||
| Non-Us | — | — | $11.75M | $11.48M | ||||||||
| Rest Of World | $807.00K | $5.44M | — | — | ||||||||
| Total | $57.97M | $91.30M | $117.27M | $133.93M |
Xtant Medical Holdings brought in $133.93M from its two regions in fiscal 2025, the year ended December 31, 2025. That is less than the $152.65M it reports by product and service, so these regions do not cover all of its revenue. United States was the largest at $122.45M (91.4%), ahead of Non-Us at $11.48M (8.6%).
Compared with fiscal 2024, United States grew 16.0% to $122.45M, while Non-Us fell 2.3% to $11.48M.
Xtant Medical Holdings began breaking out Non-Us in fiscal 2024, when it brought in $11.75M. Xtant Medical Holdings stopped reporting Rest Of World as a separate region after fiscal 2023, when it brought in $5.44M.
Us was Xtant Medical Holdings’s largest region in fiscal 2013, bringing in $32.46M of $33.04M (98%).
| Geography | FY 2011 | FY 2012 | FY 2013 |
|---|---|---|---|
| Us | — | $31.95M | $32.46M |
| United States | $29.57M | — | — |
| Rest Of World | $578.04K | $1.03M | $584.59K |
| Total | $30.15M | $32.98M | $33.04M |
Xtant Medical Holdings brought in $33.04M from its two regions in fiscal 2013, the year ended December 31, 2013. That was up 0.2% from $32.98M in fiscal 2012. Us was the largest at $32.46M (98.2%), ahead of Rest Of World at $584.59K (1.8%).
Xtant Medical Holdings began breaking out Us in fiscal 2012, when it brought in $31.95M. Xtant Medical Holdings stopped reporting United States as a separate region after fiscal 2011, when it brought in $29.57M.
Xtant Medical Holdings (XTNT) reports its revenue by product and service and by geography. In fiscal 2025, Orthobiologics was its largest product and service line, bringing in $72.89M (47.8% of the total), followed by Spinal Implant at $42.31M (27.7%).
Orthobiologics was Xtant Medical Holdings' largest product and service line in fiscal 2025, bringing in $72.89M, or 47.8% of the $152.65M total across its four product and service lines.
United States was Xtant Medical Holdings' largest region in fiscal 2025, bringing in $122.45M, or 91.4% of the $133.93M total across its two regions.
Among Xtant Medical Holdings' product and service lines that make up at least 2% of revenue, License Revenue grew fastest in fiscal 2025, up 1,146.5% from $1.50M to $18.72M.
Every figure comes from Xtant Medical Holdings' annual financial filings, as reported. Each line keeps the name Xtant Medical Holdings gives it, and years follow its fiscal calendar.
Xtant Medical Holdings' revenue by product and service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.